文献速递肿瘤 PET/CT核素与放射性配体治疗

18F-FDG PET在神经内分泌肿瘤中的预后价值优于WHO分级并可指导PRRT

18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study.
PubMed 文献 · J Nucl Med · 2020-10-16

该前瞻性队列研究纳入166例经病理确诊的胃肠胰来源神经内分泌肿瘤患者,中位随访9.8年,评估18F-FDG PET的长期预后价值并与WHO 2010组织学分级比较。结果显示18F-FDG PET阳性与更短总生存期相关(HR 3.8,95%CI 2.4-5.9,P<0.001),在G1和G2患者中为唯一高危死亡识别因素,且对接受PRRT患者的生存分层优于肿瘤分级。

要点

  • 18F-FDG PET阳性是全级别NEN患者总生存期缩短的独立预后因素(HR 3.8,95%CI 2.4-5.9,P<0.001)。
  • 在G1和G2患者中,18F-FDG PET阳性是唯一识别高死亡风险的因素(HR 3.6,95%CI 2.2-5.9,P<0.001)。
  • 接受PRRT的患者中,18F-FDG阴性者生存显著长于阳性者,而肿瘤分级未显示差异。

核心结论

  • 18F-FDG PET适用于所有NEN级别的风险分层,且优于组织学分级。
  • 18F-FDG PET可将G1和G2肿瘤区分为低危和高危组。
  • 在NEN患者治疗选择和风险分层中应考虑18F-FDG PET状态。

研究设计与样本

  • 前瞻性队列研究,纳入166例经病理确诊的胃肠胰来源NEN患者,涵盖所有级别。
  • 主要终点为总生存期(OS),次要终点为无进展生存期(PFS),探索性终点为与PRRT相关的OS。
  • 中位随访时间为9.8年。

主要发现

  • 全队列中,18F-FDG PET阳性者OS短于阴性者(HR 3.8;95%CI 2.4-5.9;P<0.001)。
  • G1和G2患者(n=140)中,18F-FDG PET阳性是唯一的高死亡风险识别因素(HR 3.6;95%CI 2.2-5.9;P<0.001)。
  • 多因素分析中,OS的独立预后因素包括18F-FDG PET、G3肿瘤、≥2个肝转移灶和≥2次既往治疗;PFS的独立预后因素包括18F-FDG PET、G3肿瘤和≥3个肝转移灶。
  • 接受PRRT的患者中,18F-FDG阴性者生存显著长于阳性者,而肿瘤分级无差异。
  • 18F-FDG阳性患者中,接受PRRT者中位生存显著长于未接受PRRT者(4.4年 vs 1.4年,P=0.001),18F-FDG阴性患者中未见差异。

临床怎么用

  • 对胃肠胰NEN患者进行风险分层时应考虑18F-FDG PET状态,尤其G1和G2患者可据此区分低危和高危。
  • 选择PRRT治疗时,18F-FDG PET状态有助于识别可能获益的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Accurate grading of patients with neuroendocrine neoplasms (NENs) is essential for risk stratification and optimal choice of therapy. Currently, grading is based on histologically assessed degree of tumor proliferation. The aim of the present study was to assess the long-term prognostic value of 18F-FDG PET imaging for risk stratification of NENs and compare it with tumor grading (World Health Organization 2010 classification). Methods: We conducted a prospective cohort study evaluating the prognostic value of 18F-FDG PET imaging and compared it with histologic grading. Enrolled were 166 patients of all grades and with histologically confirmed NENs of gastroenteropancreatic origin. The primary endpoint was overall survival (OS). Progression-free survival (PFS) was a secondary endpoint. In addition, OS in relation to peptide receptor radionuclide therapy (PRRT) was analyzed as an exploratory endpoint. The median follow-up time was 9.8 y. Results: Analysis of the whole cohort revealed that a positive 18F-FDG PET scan was associated with a shorter OS than a negative 18F-FDG PET scan (hazard ratio: 3.8; 95% CI: 2.4-5.9; P < 0.001). In G1 and G2 patients (n = 140), a positive 18F-FDG PET scan was the only identifier of high risk for death (hazard ratio: 3.6; 95% CI, 2.2-5.9; P < 0.001). In multivariate analysis, 18F-FDG PET, G3 tumor, ≥2 liver metastases, and ≥2 prior therapies were independent prognostic factors for OS, and 18F-FDG PET, G3 tumor, and ≥3 liver metastases were independent prognostic factors for PFS. For patients receiving PRRT, 18F-FDG-negative cases had a significantly longer survival than 18F-FDG-positive cases, whereas no difference was identified for tumor grading. 18F-FDG-positive patients receiving PRRT had a significantly longer median survival than patients not receiving PRRT (4.4 vs. 1.4 y, P = 0.001), whereas no difference was seen for 18F-FDG-negative patients. Conclusion:18F-FDG PET is useful for risk stratification of all NEN grades and is superior to histologic grading. 18F-FDG PET could differentiate G1 and G2 tumors into low- and high-risk groups. In the selection of therapy and for risk stratification of NEN patients, 18F-FDG PET status should be considered.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Binderup T, Knigge U, Johnbeck CB, et al. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med. 2020. PMID: 33067340. doi:10.2967/jnumed.120.244798

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。